Share this Page:
Results from a phase III trial presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting held in Chicago last week confirmed the prognostic value of a 16-gene recurrence score (RS) in patients with high-risk renal cell carcinoma (RCC) undergoing adjuvant sunitinib therapy. Though the score cannot yet be used to select patients for adjuvant therapy, it could be used to identify those who will derive the greatest benefit.
The study included a total of 193 patients with high-risk, stage III RCC, who were included in the S-TRAC study; 90 patients were treated with placebo, and 103 were treated with sunitinib.